Piracetam Treatment in Post-Stroke Aphasia View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1998-06

AUTHORS

Klaus Poeck

ABSTRACT

In the past, post-stroke aphasia (in common with aphasia of other origin) has been treated mainly by means of logopaedic language therapy, i.e. language training provided by speech therapists. So-called ‘supportive drug therapy’ was not based on conclusions drawn from controlled studies. It appeared promising to complement language therapy with the administration of appropriate drugs, the efficacy of which had been demonstrated scientifically. In animal experiments and single photon emission tomography studies in patients with acute ischaemic stroke, piracetam has been shown to improve microcirculation and neuronal metabolism, and to enhance transmitter functions. Two double-blind placebo-controlled studies in patients with chronic aphasia have demonstrated a beneficial effect of oral piracetam 4.8 g/day preceded by intravenous bolus injection of 12g, as measured by improvement in some functionally important scores of the Aachen Aphasia Test. In a further 3 double-blind placebo-controlled studies in patients with acute stroke, it was shown that improvement of aphasia was significantly greater in the group receiving piracetam than in the placebo group. Particular mention is made of a study (the Piracetam Acute Stroke Study) in patients with acute stroke. These patients received placebo or intravenous piracetam 12 g/day for 5 days followed by oral piracetam 12 g/day until the end of week 4, and 4 to 8 g/day until the end of week 8. After 12 weeks of treatment, significantly more piracetam-treated patients who had initially presented with aphasia were no longer aphasia compared with the placebo group. More... »

PAGES

51-56

Identifiers

URI

http://scigraph.springernature.com/pub.10.2165/00023210-199809001-00006

DOI

http://dx.doi.org/10.2165/00023210-199809001-00006

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1007980371


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "RWTH Aachen University", 
          "id": "https://www.grid.ac/institutes/grid.1957.a", 
          "name": [
            "Department of Neurology, RWTH, Aachen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Poeck", 
        "givenName": "Klaus", 
        "id": "sg:person.064377522.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.064377522.07"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1097/00002826-199408000-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001897904"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(84)91690-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015149608"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(84)91690-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015149608"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmj.2.6182.87", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017342509"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/archneur.1979.00500400044005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027377993"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/03790798709166209", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029122663"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/archneur.1987.00520180064018", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029970066"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/02687039208248605", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040545159"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1044/jshd.5403.471", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041083457"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1006/brln.1994.1060", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041498747"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/archneur.1986.00520070011008", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045640129"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0003-9993(97)90028-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052957285"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.str.28.12.2347", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063342209"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078884474", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081137871", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081619896", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1998-06", 
    "datePublishedReg": "1998-06-01", 
    "description": "In the past, post-stroke aphasia (in common with aphasia of other origin) has been treated mainly by means of logopaedic language therapy, i.e. language training provided by speech therapists. So-called \u2018supportive drug therapy\u2019 was not based on conclusions drawn from controlled studies. It appeared promising to complement language therapy with the administration of appropriate drugs, the efficacy of which had been demonstrated scientifically. In animal experiments and single photon emission tomography studies in patients with acute ischaemic stroke, piracetam has been shown to improve microcirculation and neuronal metabolism, and to enhance transmitter functions. Two double-blind placebo-controlled studies in patients with chronic aphasia have demonstrated a beneficial effect of oral piracetam 4.8 g/day preceded by intravenous bolus injection of 12g, as measured by improvement in some functionally important scores of the Aachen Aphasia Test. In a further 3 double-blind placebo-controlled studies in patients with acute stroke, it was shown that improvement of aphasia was significantly greater in the group receiving piracetam than in the placebo group. Particular mention is made of a study (the Piracetam Acute Stroke Study) in patients with acute stroke. These patients received placebo or intravenous piracetam 12 g/day for 5 days followed by oral piracetam 12 g/day until the end of week 4, and 4 to 8 g/day until the end of week 8. After 12 weeks of treatment, significantly more piracetam-treated patients who had initially presented with aphasia were no longer aphasia compared with the placebo group.", 
    "genre": "research_article", 
    "id": "sg:pub.10.2165/00023210-199809001-00006", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1111875", 
        "issn": [
          "1172-7047", 
          "1179-1934"
        ], 
        "name": "CNS Drugs", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "Suppl 1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "9"
      }
    ], 
    "name": "Piracetam Treatment in Post-Stroke Aphasia", 
    "pagination": "51-56", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "2604b8aea0d12a7e056b3577bc30b636583ce4c9a9f182903cb4ca03af0ee183"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.2165/00023210-199809001-00006"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1007980371"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.2165/00023210-199809001-00006", 
      "https://app.dimensions.ai/details/publication/pub.1007980371"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T20:45", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8684_00000503.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.2165/00023210-199809001-00006"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00023210-199809001-00006'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00023210-199809001-00006'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00023210-199809001-00006'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00023210-199809001-00006'


 

This table displays all metadata directly associated to this object as RDF triples.

103 TRIPLES      21 PREDICATES      42 URIs      19 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.2165/00023210-199809001-00006 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N06ada85fb4d74cedb7e1dc6d6fa505e9
4 schema:citation https://app.dimensions.ai/details/publication/pub.1078884474
5 https://app.dimensions.ai/details/publication/pub.1081137871
6 https://app.dimensions.ai/details/publication/pub.1081619896
7 https://doi.org/10.1001/archneur.1979.00500400044005
8 https://doi.org/10.1001/archneur.1986.00520070011008
9 https://doi.org/10.1001/archneur.1987.00520180064018
10 https://doi.org/10.1006/brln.1994.1060
11 https://doi.org/10.1016/s0003-9993(97)90028-9
12 https://doi.org/10.1016/s0140-6736(84)91690-8
13 https://doi.org/10.1044/jshd.5403.471
14 https://doi.org/10.1080/02687039208248605
15 https://doi.org/10.1097/00002826-199408000-00003
16 https://doi.org/10.1136/bmj.2.6182.87
17 https://doi.org/10.1161/01.str.28.12.2347
18 https://doi.org/10.3109/03790798709166209
19 schema:datePublished 1998-06
20 schema:datePublishedReg 1998-06-01
21 schema:description In the past, post-stroke aphasia (in common with aphasia of other origin) has been treated mainly by means of logopaedic language therapy, i.e. language training provided by speech therapists. So-called ‘supportive drug therapy’ was not based on conclusions drawn from controlled studies. It appeared promising to complement language therapy with the administration of appropriate drugs, the efficacy of which had been demonstrated scientifically. In animal experiments and single photon emission tomography studies in patients with acute ischaemic stroke, piracetam has been shown to improve microcirculation and neuronal metabolism, and to enhance transmitter functions. Two double-blind placebo-controlled studies in patients with chronic aphasia have demonstrated a beneficial effect of oral piracetam 4.8 g/day preceded by intravenous bolus injection of 12g, as measured by improvement in some functionally important scores of the Aachen Aphasia Test. In a further 3 double-blind placebo-controlled studies in patients with acute stroke, it was shown that improvement of aphasia was significantly greater in the group receiving piracetam than in the placebo group. Particular mention is made of a study (the Piracetam Acute Stroke Study) in patients with acute stroke. These patients received placebo or intravenous piracetam 12 g/day for 5 days followed by oral piracetam 12 g/day until the end of week 4, and 4 to 8 g/day until the end of week 8. After 12 weeks of treatment, significantly more piracetam-treated patients who had initially presented with aphasia were no longer aphasia compared with the placebo group.
22 schema:genre research_article
23 schema:inLanguage en
24 schema:isAccessibleForFree false
25 schema:isPartOf N2971ef3d338c4cfb8e167171ab29faba
26 Ndd37dfd52e1e45019b16a62bf8893145
27 sg:journal.1111875
28 schema:name Piracetam Treatment in Post-Stroke Aphasia
29 schema:pagination 51-56
30 schema:productId N4af2b07893ca4d5db1d1246925c2c112
31 Ne53b59a67dac4f8d927e77512a27882f
32 Nfff0bc7e13804fb09b312636ef0c4cca
33 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007980371
34 https://doi.org/10.2165/00023210-199809001-00006
35 schema:sdDatePublished 2019-04-10T20:45
36 schema:sdLicense https://scigraph.springernature.com/explorer/license/
37 schema:sdPublisher Nf1c10345ea2f407395c1d8f5e7da3bc9
38 schema:url http://link.springer.com/10.2165/00023210-199809001-00006
39 sgo:license sg:explorer/license/
40 sgo:sdDataset articles
41 rdf:type schema:ScholarlyArticle
42 N06ada85fb4d74cedb7e1dc6d6fa505e9 rdf:first sg:person.064377522.07
43 rdf:rest rdf:nil
44 N2971ef3d338c4cfb8e167171ab29faba schema:issueNumber Suppl 1
45 rdf:type schema:PublicationIssue
46 N4af2b07893ca4d5db1d1246925c2c112 schema:name dimensions_id
47 schema:value pub.1007980371
48 rdf:type schema:PropertyValue
49 Ndd37dfd52e1e45019b16a62bf8893145 schema:volumeNumber 9
50 rdf:type schema:PublicationVolume
51 Ne53b59a67dac4f8d927e77512a27882f schema:name readcube_id
52 schema:value 2604b8aea0d12a7e056b3577bc30b636583ce4c9a9f182903cb4ca03af0ee183
53 rdf:type schema:PropertyValue
54 Nf1c10345ea2f407395c1d8f5e7da3bc9 schema:name Springer Nature - SN SciGraph project
55 rdf:type schema:Organization
56 Nfff0bc7e13804fb09b312636ef0c4cca schema:name doi
57 schema:value 10.2165/00023210-199809001-00006
58 rdf:type schema:PropertyValue
59 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
60 schema:name Medical and Health Sciences
61 rdf:type schema:DefinedTerm
62 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
63 schema:name Clinical Sciences
64 rdf:type schema:DefinedTerm
65 sg:journal.1111875 schema:issn 1172-7047
66 1179-1934
67 schema:name CNS Drugs
68 rdf:type schema:Periodical
69 sg:person.064377522.07 schema:affiliation https://www.grid.ac/institutes/grid.1957.a
70 schema:familyName Poeck
71 schema:givenName Klaus
72 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.064377522.07
73 rdf:type schema:Person
74 https://app.dimensions.ai/details/publication/pub.1078884474 schema:CreativeWork
75 https://app.dimensions.ai/details/publication/pub.1081137871 schema:CreativeWork
76 https://app.dimensions.ai/details/publication/pub.1081619896 schema:CreativeWork
77 https://doi.org/10.1001/archneur.1979.00500400044005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027377993
78 rdf:type schema:CreativeWork
79 https://doi.org/10.1001/archneur.1986.00520070011008 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045640129
80 rdf:type schema:CreativeWork
81 https://doi.org/10.1001/archneur.1987.00520180064018 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029970066
82 rdf:type schema:CreativeWork
83 https://doi.org/10.1006/brln.1994.1060 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041498747
84 rdf:type schema:CreativeWork
85 https://doi.org/10.1016/s0003-9993(97)90028-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052957285
86 rdf:type schema:CreativeWork
87 https://doi.org/10.1016/s0140-6736(84)91690-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015149608
88 rdf:type schema:CreativeWork
89 https://doi.org/10.1044/jshd.5403.471 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041083457
90 rdf:type schema:CreativeWork
91 https://doi.org/10.1080/02687039208248605 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040545159
92 rdf:type schema:CreativeWork
93 https://doi.org/10.1097/00002826-199408000-00003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001897904
94 rdf:type schema:CreativeWork
95 https://doi.org/10.1136/bmj.2.6182.87 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017342509
96 rdf:type schema:CreativeWork
97 https://doi.org/10.1161/01.str.28.12.2347 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063342209
98 rdf:type schema:CreativeWork
99 https://doi.org/10.3109/03790798709166209 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029122663
100 rdf:type schema:CreativeWork
101 https://www.grid.ac/institutes/grid.1957.a schema:alternateName RWTH Aachen University
102 schema:name Department of Neurology, RWTH, Aachen, Germany
103 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...